Table 4 |
|||||||
|
Results of immunohistochemical stainings |
|||||||
|
Scoring |
HER1 (n = 48) |
HER3 (n = 47) |
HER4 (n = 48) |
phospho-HER2 (n = 43) |
p27Kip1 (n = 48) |
ERα (n = 45) |
PR (n = 46) |
|
|
|||||||
|
0 |
37 (77.1) |
8 (16.7) |
22 (45.8) |
36 (83.7) |
n/a |
n/a |
n/a |
|
1 |
7 (14.6) |
31 (64.6) |
7 (14.6) |
3 (7.0) |
n/a |
n/a |
n/a |
|
2 |
3 (6.2) |
8 (16.7) |
12 (25.0) |
4 (9.3) |
n/a |
n/a |
n/a |
|
3 |
1 (2.1) |
0 |
7 (14.6) |
0 |
n/a |
n/a |
n/a |
|
Negative |
37 (77.1) |
8 (16.7) |
22 (45.8) |
36 (83.7) |
24 (50.0) |
19 (42.2) |
29 (63.0) |
|
Positive |
11 (22.9) |
39 (81.2) |
26 (54.2) |
7 (16.3) |
24 (50.0) |
26 (57.8) |
17 (37.0) |
|
|
|||||||
|
All 48 patients were HER2 FISH positive (ratio > 1.5). Numbers in parentheses are percentages. Results in bold define data considered positive for immunohistochemistry. n/a = not applicable, scoring defined in methodical chapter. ER = oestrogen receptor; HER = human epidermal growth factor receptor; PR = Progesterone receptor. |
|||||||
|
Sassen et al. Breast Cancer Research 2009 11:R50 doi:10.1186/bcr2339 |
|||||||